Veterans and Servicemembers PTSD Emerging Treatment Review Act of 2026

This bill directs the Department of Defense to review clinical trial data on psilocybin treatment for veterans and servicemembers with treatment-resistant PTSD. It requires the Assistant Secretary of Defense for Health Affairs to submit a report within 180 days analyzing the safety, dosing, and feasibility of these findings for military personnel, including those transitioning to civilian life. The report must also assess legal requirements for expanded access to the substance and outline plans for future pilot programs or research starting in fiscal year 2027. Additionally, the legislation mandates coordination with the Department of Veterans Affairs and other federal agencies to ensure continuity of care and appropriate regulatory oversight.